Spyre Therapeutics, Inc.
SYRE
$16.67
$0.784.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -3.55% | -74.43% | |||
| Gross Profit | 3.55% | 74.43% | |||
| SG&A Expenses | -1.29% | 10.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.05% | -12.55% | |||
| Operating Income | 3.05% | 12.55% | |||
| Income Before Tax | 18.02% | 20.44% | |||
| Income Tax Expenses | -- | -1,600.00% | |||
| Earnings from Continuing Operations | 17.99% | 20.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.99% | 20.47% | |||
| EBIT | 3.05% | 12.55% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 18.07% | -1,627.55% | |||
| Normalized Basic EPS | -4.18% | 27.05% | |||
| EPS Diluted | 18.07% | -1,627.55% | |||
| Normalized Diluted EPS | -4.18% | 27.05% | |||
| Average Basic Shares Outstanding | 0.11% | 9.06% | |||
| Average Diluted Shares Outstanding | 0.11% | 9.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||